Application of isoproterenol inhibits diabetic-like changes in the rat retina

Experimental Eye Research

Volumn 91, Issue 2, 2010, Pages 171-179

  Jiang, Youde ^a   Walker, Robert J ^a   Kern, Timothy S ^b   Steinle, Jena J ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

adrenergic receptors; Apoptosis; Diabetic retinopathy; Insulin receptor signaling; Sympathetic nerves

Indexed keywords

INSULIN RECEPTOR KINASE; ISOPRENALINE; STREPTOZOCIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC RETINOPATHY; ELECTRIC ACTIVITY; GLUCOSE BLOOD LEVEL; MALE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RETINA CELL; STREPTOZOCIN DIABETES;

ADRENERGIC BETA-AGONISTS; ANIMALS; BLOTTING, WESTERN; CASPASE 3; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; ELECTRORETINOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; ISOPROTERENOL; MALE; OPHTHALMIC SOLUTIONS; PHOSPHORYLATION; RATS; RATS, INBRED LEW; RETINA; RETINAL VESSELS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954957983     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2010.04.014     Document Type: Article

References (32)

1. Antonetti D.A., Barber A.J., Bronson S.K., Freeman W.M., Gardner T.W., Jefferson L.S., Kester M., Kimball S.R., Krady J.K., LaNoue K.F., Norbury C.C., Quinn P.G., Sandirasegarane L., Simpson I.A. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 2006, 55:2401-2411.
2. Baltensperger K., Karoor V., Paul H., Ruoho A., Czech M.P., Malbon C.C. The beta-adrenergic receptor is a substrate for the insulin receptor tyrosine kinase. J. Biol. Chem. 1996, 271:1061-1064.
3. Barber A.J., Lieth E., Khin S.A., Antonetti D.A., Buchanan A.G., Gardner T.W. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J. Clin. Invest. 1998, 102:783-791.
4. Barber A.J., Nakamura M., Wolpert E.B., Reiter C.E., Seigel G.M., Antonetti D.A., Gardner T.W. Insulin rescues retinal neurons from apoptosis by a phosphatidylinositol 3-kinase/Akt-mediated mechanism that reduces the activation of caspase-3. J. Biol. Chem. 2001, 276:32814-32821.
5. Engerman R.L., Kern T.S. Retinopathy in animal models of diabetes. Diabetes Metab. Rev. 1995, 11:109-120.
6. Forte J.D., Bui B.V., Vingrys A.J. Wavelet analysis reveals dynamics of rat oscillatory potentials. J. Neurosci. Methods 2007, 169:191-200.
7. Gardner T.W., Antonetti D.A., Barber A.J., LaNoue K.F., Levison S.W. Diabetic retinopathy: more than meets the eye. Surv. Ophthalmol. 2002, 47(Suppl. 2):S253-S262.
8. Gavi S., Yin D., Shumay E., Wang H.Y., Malbon C.C. The 15-amino acid motif of the C terminus of the beta2-adrenergic receptor is sufficient to confer insulin-stimulated counterregulation to the beta1-adrenergic receptor. Endocrinology 2005, 146:450-457.
9. Hirooka K., Kelly M.E., Baldridge W.H., Barnes S. Suppressive actions of betaxolol on ionic currents in retinal ganglion cells may explain its neuroprotective effects. Exp. Eye Res. 2000, 70:611-621.
10. Jiang Y., Steinle J.J. Systemic propranolol reduces B-wave amplitude in the ERG and increases IGF-1 receptor phosphorylation in rat retina. Invest. Ophthalmol. Vis. Sci. 2010, 51(5):2730-2735.
11. Joussen A.M., Huang S., Poulaki V., Camphausen K., Beecken W.D., Kirchhof B., Adamis A.P. In vivo retinal gene expression in early diabetes. Invest. Ophthalmol. Vis. Sci. 2001, 42:3047-3057.
12. Joussen A.M., Poulaki V., Le M.L., Koizumi K., Esser C., Janicki H., Schraermeyer U., Kociok N., Fauser S., Kirchhof B., Kern T.S., Adamis A.P. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004, 18:1450-1452.
13. Kawabe J., Aizawa Y., Takehara N., Hasebe N., Kikuchi K. Glucose modifies the cross-talk between insulin and the beta-adrenergic signalling system in vascular smooth muscle cells. J. Hypertens. 2000, 18:1457-1464.
14. Kern T.S., Engerman R.L. Comparison of retinal lesions in alloxan-diabetic rats and galactose-fed rats. Curr. Eye Res. 1994, 13:863-867.
15. Kern T.S., Miller C.M., Du Y., Zheng L., Mohr S., Ball S.L., Kim M., Jamison J.A., Bingaman D.P. Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology. Diabetes 2007, 56:373-379.
16. Kowluru R.A., Tang J., Kern T.S. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes 2001, 50:1938-1942.
17. Mizutani M., Kern T.S., Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J. Clin. Invest. 1996, 97:2883-2890.
18. Osborne N.N., Wood J.P., Chidlow G. Invited review: neuroprotective properties of certain beta-adrenoceptor antagonists used for the treatment of glaucoma. J. Ocul. Pharmacol. Ther. 2005, 21:175-181.
19. Phipps J.A., Wilkinson-Berka J.L., Fletcher E.L. Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol. Invest. Ophthalmol. Vis. Sci. 2007, 48:927-934.
20. Reiter C.E., Gardner T.W. Functions of insulin and insulin receptor signaling in retina: possible implications for diabetic retinopathy. Prog. Retin. Eye Res. 2003, 22:545-562.
21. Reiter C.E., Wu X., Sandirasegarane L., Nakamura M., Gilbert K.A., Singh R.S., Fort P.E., Antonetti D.A., Gardner T.W. Diabetes reduces basal retinal insulin receptor signaling: reversal with systemic and local insulin. Diabetes 2006, 55:1148-1156.
22. Schmidt R.E. Age-related sympathetic ganglionic neuropathology: human pathology and animal models. Auton. Neurosci. 2002, 96:63-72.
23. Steinle J.J. Sympathetic neurotransmission modulates expression of inflammatory markers in the rat retina. Exp. Eye Res. 2007, 84:118-125.
24. Steinle J.J., Chin V.C., Williams K.P., Panjala S.R. Beta-adrenergic receptor stimulation modulates iNOS protein levels through p38 and ERK1/2 signaling in human retinal endothelial cells. Exp. Eye Res. 2008, 87:30-34.
25. Steinle J.J., Kern T.S., Thomas S.A., McFadyen-Ketchum L.S., Smith C.P. Increased basement membrane thickness, pericyte ghosts, and loss of retinal thickness and cells in dopamine beta hydroxylase knockout mice. Exp. Eye Res. 2009, 88:1014-1019.
26. Steinle J.J., Lindsay N.L., Lashbrook B.L. Cervical sympathectomy causes photoreceptor-specific cell death in the rat retina. Auton. Neurosci. 2005, 120:46-51.
27. Sun W., Oates P.J., Coutcher J.B., Gerhardinger C., Lorenzi M. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes 2006, 55:2757-2762.
28. Walker R., Steinle J. Role of beta-adrenergic receptors in inflammatory marker expression in Muller Cells. Invest. Ophthalmol. Vis. Sci. 2007, 48:5276-5281.
29. Weymouth A.E., Vingrys A.J. Rodent electroretinography: methods for extraction and interpretation of rod and cone responses. Prog. Retin. Eye Res. 2008, 27:1-44.
30. Wiley L.A., Rupp G.R., Steinle J.J. Sympathetic innervation regulates basement membrane thickening and pericyte number in rat retina. Invest. Ophthalmol. Vis. Sci. 2005, 46:744-748.
31. Wilkinson-Berka J.L., Tan G., Jaworski K., Ninkovic S. Valsartan but not atenolol improves vascular pathology in diabetic Ren-2 rat retina. Am. J. Hypertens. 2007, 20:423-430.
32. Wolter J.R. Diabetic retinopathy. Am. J. Ophthalmol. 1961, 51:1123-1141.